> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Moderna Cuts Borrowing Margins On $1.5 Billion Credit Deal And Pushes Repayment To 2031
- URL: https://www.bullished.co/moderna-cuts-borrowing-margins-on-1-5-billion-credit-deal-and-pushes-repayment-to-2031-05f26a8b/
- Published: 2026-11-16T22:35:53.000Z
- Updated: 2026-11-16T22:35:53.000Z
- Description: The revised agreement extends borrowing windows, but access to $500 million still hinges on an eligible product winning FDA approval.
- Author: Matteo Parrino
- Tags: SEC Filings, MRNA, Industry: Healthcare

[Moderna](https://www.bullished.co/tag/mrna/), which develops mRNA medicines and vaccines, secured lower borrowing margins and a later repayment deadline under its [$1.5 billion agreement](https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000208/mrna-20261109.htm?ref=bullished.co). The changes took effect Monday, November 9, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Monday, and move scheduled loan repayment to November 24, 2031, from November 24, 2030.

## Lower Surcharges, Later Repayment

Moderna and its lenders, with Ares Capital acting as their agent, cut the interest margins on initial and delayed-draw loans by 0.75 percentage points.

Loans linked to the Secured Overnight Funding Rate, or SOFR, now carry a 4.75% surcharge, down from 5.50%. The margin on base-rate loans fell to 3.75% from 4.50%; those margins are added to the underlying benchmark rates.

The later maturity remains subject to provisions allowing earlier repayment. Moderna established the financing on November 19, 2025, allocating [$600 million](https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000208/moderna-firstamendmentexec.htm?ref=bullished.co) to initial term loans for working capital and general corporate purposes. Collateral, with exclusions, and guarantees from participating subsidiaries continue to back the obligations.

## FDA Approval Still Gates $500 Million

Moderna has until November 24, 2029, to borrow against both delayed-draw commitments, subject to earlier termination. The [$400 million commitment](https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000208/mrna-20261109.htm?ref=bullished.co) previously expired on November 24, 2027; the $500 million portion previously expired on November 24, 2028.

Access to that $500 million still requires FDA approval of an eligible product. Qualifying candidates include Moderna's combined COVID-flu vaccine, its flu vaccine and its norovirus vaccines.

The revised agreement also allows unsecured borrowing convertible into shares or cash. That debt is capped at 10% of Moderna's market capitalization when issued, with restrictions on maturity, covenants and other terms.

## COVID Sales Support A Wider Pipeline

Moderna reported $1.9 billion in revenue for 2025, largely from COVID vaccines. Its commercial products are Spikevax and mNEXSPIKE for COVID, plus mRESVIA against respiratory syncytial virus, or RSV.

Its development pipeline includes 35 vaccine and therapeutic programs, six in late-stage development, covering infectious diseases, cancer and rare diseases. Moderna works with Merck on an individualized cancer therapy and with Recordati on a rare disease treatment.

The company operates a global manufacturing network, including facilities it built and manages in the UK, Canada and Australia.

The longer borrowing window preserves time to meet the product-approval condition; FDA clearance remains the gate to the $500 million portion.

Learn

- [Item 1.01: entry into a material agreement →](https://www.bullished.co/learn/8-k-items-explained/#item-101-entry-into-a-material-agreement)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Moderna, Inc. (MRNA)](https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000208/mrna-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit moderna-firstamendmentexec.htm — Moderna, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000208/moderna-firstamendmentexec.htm?ref=bullished.co) — SEC EDGAR

### More on Moderna

- [Moderna Ties Legal Chief's Retirement Payments To Litigation, Including Up To $5.5 Million](https://www.bullished.co/moderna-ties-legal-chiefs-retirement-payments-to-litigation-including-up-to-5-5-million-25a2d337/)
- [Blackstone Funding Trims Moderna’s Research Bill By $69 Million — With Future Sales Payments Attached](https://www.bullished.co/blackstone-funding-trims-modernas-research-bill-by-69-million-with-future-sales-payments-c35dfdad/)
- [Moderna Stock Soars 9.26% After Raising Sales Outlook — Adding $8.9 Billion In Market Value](https://www.bullished.co/moderna-stock-soars-9-26-after-raising-sales-outlook-adding-8-9-billion-in-market-value-d873301a/)

[All Moderna (MRNA) coverage →](https://www.bullished.co/tag/mrna/)